Post-approval changes in Labelling regulations in the United States, European Union and Canada
Abstract
The review “Post-approval changes in Labelling Regulations in the United States, Europe and Canada” goes into the details and consequences of post-approval changes in labeling regulations for pharmaceutical products. It covers the concept of post-approval changes and outlines the key areas of changes, such as various elements of product lifecycle management, market access, innovation, risk control, and legal compliance for manufacturers in the United States, Europe, and Canada. Apart from that, the abstract discusses the similarities and differences in labeling regulations across the regions in authority, structure, and the affected changes. In summary, the abstract outlines the complexities and effects of post-approval-related changes in labeling regulations concerning the pharmaceutical industry in multiple jurisdictions and the challenges encountered in implementing them. More specifically, the issues include differing regulatory frameworks and varying interpretations; operator compliance, safety evaluation and management; consolidation approaches; and the influence of digitalization and automation as a pivotal and minor player.
Downloads
References
2. Borges BJ, Arantes OM, Fernandes AA, Broach JR, Fernandes PM. Genetically modified labeling policies: Moving forward or backward? Frontiers in Bioengineering and Biotechnology. 2018 Nov 27;6:181.
3. Chakraborty K, Yadav K. Drug approval process in US, Europe and India and its regulatory requirements: A Review. Int J Drug Reg Affairs [Internet]. 2018 Sep.15 [cited 2024 Mar.20];6(3):31-9. Available from:
https://www.ijdra.com/index.php/journal/article/view/266
4. Meghraj S. An overview on comparative study of registration requirements for generics in US, Canada and Europe. International Journal of Research in Pharmaceutical Sciences and Technology. 2020 Jul 2;1(4):117-23.
5. Corny J, Lebel D, Bailey B, Bussières JF. Unlicensed and off-label drug use in children before and after pediatric governmental initiatives. The journal of pediatric pharmacology and therapeutics. 2015 Aug 1;20(4):316-28.
6. You H, Abraham EJ, Mulligan J, Zhou Y, Montoya M, Willig J, Chen BK, Wang CK, Wang LS, Dong A, Shamtsyan M. Label compliance for ingredient verification: Regulations, approaches, and trends for testing botanical products marketed for “immune health” in the United States. Critical Reviews in Food Science and Nutrition. 2024 Apr 2;64(9):2441-60.
7. Ahmed SS, Shailesh T, Kumar HS, Gangadharappa HV, Gowrav MP. An overview on post approval changes to an approved ANDA in US-FDA. Research Journal of Pharmacy and Technology. 2021;14(1):506-12.
8. Ankit, T., Shrikalp, D., Maitreyi, Z., Praveenkumar, J. and Kiran, K. Regulatory Procedure of Post Approval Changes and Comparative Requirements of EU and USA Regulatory Regions. Journal of Pharmaceutical Research International. 2021; 33(46B):304-317
9. Cooper RM. Drug Labeling and Products Liability: The Role of the Food and Drug Administration. Food, Drug, Cosmetic Law Journal. 1986 Jul 1;41(3):233-40.
10. Abedtash H, Duke J D. An interactive user interface for drug labeling to improve readability and decision-making. AMIA Annu. Symp. Proc. 2015; 2015:278-286.
11. Davis T.C., Wolf M.S., Pat F. Bass I.I.I., Thompson J.A., Tilson H.H., Neuberger M.M., Parker R.M. Literacy and misunderstanding prescription drug labels. Ann. Int. Med. 2006;145:887-894.
12. King J.P, Davis T.C, Bailey S.C, Jacobson K.L, Hedlund L.A, Di Francesco L., Parker R.M., Wolf M.S. Developing consumer-centered, non-prescription drug labeling. Am. J. Prev. Med. 2016; 40:593-598.
13. Himazawa R, Ikeda M. Safety information in drug labeling: a comparison of the USA, the UK, and Japan. Pharmacoepidemiol. Drug Saf. 2013;22:306-318.
14. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of Pharmacometrics on drug approval and Labeling decisions: a survey of 42 new drug applications. AAPSJ. 2005;7:E503-12
15. Avorn J, Shrank W. Highlights and a hidden hazard--the FDA’s new labeling regulations. N Engl J Med. 2006;354(23):2409-11
16. Woosley RL. Drug labeling revisions—guaranteed to fail? JAMA. 2000;284(23):3047-9
17. U.S. Food and Drug Administration Structured Product Labeling Resources [Internet]. USFDA; 2024 Feb 23 [cited 2024 Mar 26]. Available from:
https://www.fda.gov/industry/fda-data-standards-advisory-board/structured-product-labeling-resources
18. Cooper RM. Drug Labeling and Products Liability: The Role of the Food and Drug Administration. Food, Drug, Cosmetic Law Journal. 1986 Jul 1;41(3):233-40.
19. FDA. Challenge and Opportunity on the Critical Path to New Medicinal Products [Internet]. USFDA; 2004 Mar [cited 2024 Mar 24]. Available from:
http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf
20. IRA RB, Robert PM. The Pharmaceutical Regulatory Process. 2nd ed. Informa healthcare; 2008. p. 46-48.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
